PD-L1与Treg在肿瘤免疫及治疗中的相关性

doi:10.3760/cma.j.cn371439-20200907-00066

摘要/Abstract

摘要：

程序性死亡蛋白(PD-1)及其程序性死亡蛋白配体(PD-L1)是重要的共抑制分子,调节性T细胞(Treg)是重要的抑制性细胞,二者在肿瘤微环境中数量均增加,与肿瘤免疫逃逸及肿瘤发生发展密切相关。PD-L1对Treg的发育及功能有重要影响,抗PD-1/PD-L1抗体的应用可影响Treg的增殖和功能,进而介导耐药及超进展性疾病的发生。深入了解PD-L1与Treg在肿瘤免疫及免疫治疗中的作用及相关性,可为提高抗PD-1/PD-L1抗体疗效提供新的思路。

关键词: 肿瘤逃逸, T淋巴细胞,调节性, PD-1/PD-L1, 免疫治疗

Abstract:

Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are important co-inhibitory molecules, while regulatory T cells (Tregs) are important suppressor cells. The increase of them in tumor microenvironment is closely related to tumor immune escape and tumor development. PD-L1 plays an important role in the development and function of Tregs. The application of PD-1/PD-L1 blockade also affects the proliferation and function of Tregs, which further participates in the occurrence of drug resistance and hyperprogressive disease. Further understanding of the role and correlation of PD-L1 and Tregs in tumor immunity and immunotherapy can provide new ideas for improving the efficacy of PD-1/PD-L1 blockade.

Key words: Tumor escape, T-lymphocytes,regulatory, PD-1/PD-L1, Immunotherapy

欧惠仪, 王越, 彭承宏. PD-L1与Treg在肿瘤免疫及治疗中的相关性[J]. 国际肿瘤学杂志, 2021, 48(6): 350-353.

Ou Huiyi, Wang Yue, Peng Chenghong. Correlation between PD-L1 and Tregs in tumor immunity and immunotherapy[J]. Journal of International Oncology, 2021, 48(6): 350-353.

参考文献 27

[1]	Jiang Y, Zhao X, Fu J, et al. Progress and challenges in precise treatment of tumors with PD-1/PD-L1 blockade[J]. Front Immunol, 2020,11:339. DOI: 10.3389/fimmu.2020.00339. doi: 10.3389/fimmu.2020.00339
[2]	Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape[J]. Mol Cancer, 2019,18(1):10. DOI: 10.1186/s12943-018-0928-4. doi: 10.1186/s12943-018-0928-4
[3]	Zhou AL, Wang X, Yu W, et al. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma[J]. Pathol Res Pract, 2020,216(9):153093. DOI: 10.1016/j.prp.2020.153093. doi: 10.1016/j.prp.2020.153093
[4]	Hu ZQ, Xin HY, Luo CB, et al. Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma[J]. Cancer Immunol Immuno-ther, 2021,70(2):377-389. DOI: 10.1007/s00262-020-02685-7.
[5]	Sun C, Zhang L, Zhang W, et al. Expression of PD-1 and PD-L1 on tumor-infiltrating lymphocytes predicts prognosis in patients with small-cell lung cancer[J]. Onco Targets Ther, 2020,13:6475-6483. DOI: 10.2147/OTT.S252031. doi: 10.2147/OTT.S252031
[6]	Kowanetz M, Zou W, Gettinger SN, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)[J]. Proc Natl Acad Sci U S A, 2018,115(43):E10119-E10126. DOI: 10.1073/pnas.1802166115. doi: 10.1073/pnas.1802166115
[7]	Patsoukis N, Duke-Cohan JS, Chaudhri A, et al. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation[J]. Commun Biol, 2020,3(1):128. DOI: 10.1038/s42003-020-0845-0. doi: 10.1038/s42003-020-0845-0 pmid: 32184441
[8]	Cai J, Wang D, Zhang G, et al. The role of PD-1/PD-L1 axis in Treg development and function: implications for cancer immunotherapy[J]. Onco Targets Ther, 2019,12:8437-8445. DOI: 10.2147/OTT.S221340. doi: 10.2147/OTT
[9]	Cui P, Jing P, Liu X, et al. Prognostic significance of PD-L1 expre-ssion and its tumor-intrinsic functions in hypopharyngeal squamous cell carcinoma[J]. Cancer Manag Res, 2020,12:5893-5902. DOI: 10.2147/CMAR.S257299. doi: 10.2147/CMAR.S257299
[10]	Al Dulaijan BS, Mansouri A, Karnyski J, et al. Regulatory T cells: from the bench to the clinic and back[J]. Curr Opin Organ Transplant, 2018,23(1):1-7. DOI: 10.1097/MOT.0000000000000491. doi: 10.1097/MOT.0000000000000491 pmid: 29210727
[11]	Zhang LN, Xin T, Chen M, et al. Chemoresistance in mesenchymal lung cancer cells is correlated to high regulatory T cell presence in the tumor microenvironment[J]. IUBMB Life, 2019,71(7):986-991. DOI: 10.1002/iub.2043.
[12]	Kuehnemuth B, Piseddu I, Wiedemann GM, et al. CCL1 is a major regulatory T cell attracting factor in human breast cancer[J]. BMC Cancer, 2018,18(1):1278. DOI: 10.1186/s12885-018-5117-8. doi: 10.1186/s12885-018-5117-8 pmid: 30572845
[13]	Syed Khaja AS, Toor SM, El Salhat H, et al. Intratumoral FOXP3⁺ Helios⁺ regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal cancer[J]. Front Immunol, 2017,8:619. DOI: 10.3389/fimmu.2017.00619. doi: 10.3389/fimmu.2017.00619
[14]	Shang B, Liu Y, Jiang SJ, et al. Prognostic value of tumor-infiltrating FOXP3⁺ regulatory T cells in cancers: a systematic review and meta-analysis[J]. Sci Rep, 2015,5:15179. DOI: 10.1038/srep15179. doi: 10.1038/srep15179
[15]	Park HJ, Park JS, Jeong YH, et al. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8⁺ T cell immune response via the interaction with PD-L1 expressed on CD8⁺ T cells[J]. J Immunol, 2015,194(12):5801-5811. DOI: 10.4049/jimmunol.1401936. doi: 10.4049/jimmunol.1401936
[16]	Rueda CM, Jackson CM, Chougnet CA. Regulatory T-cell-mediated suppression of conventional T-cells and dendritic cells by different cAMP intracellular pathways[J]. Front Immunol, 2016,7:216. DOI: 10.3389/fimmu.2016.00216.
[17]	Stathopoulou C, Gangaplara A, Mallett G, et al. PD-1 inhibitory receptor downregulates asparaginyl endopeptidase and maintains FOXP3 transcription factor stability in induced regulatory T cells[J]. Immunity, 2018, 49(2): 247-263.e7. DOI: 10.1016/j.immuni.2018.05.006. doi: S1074-7613(18)30242-5 pmid: 30054205
[18]	Lin CL, Huang HM, Hsieh CL, et al. Jagged1-expressing adenovirus-infected dendritic cells induce expansion of Foxp3⁺ regulatory T cells and alleviate T helper type 2-mediated allergic asthma in mice[J]. Immunology, 2019,156(2):199-212. DOI: 10.1111/imm.13021. doi: 10.1111/imm.2019.156.issue-2
[19]	Dong Y, Han Y, Huang Y, et al. PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia[J]. Front Immunol, 2020,11:1710. DOI: 10.3389/fimmu.2020.01710. doi: 10.3389/fimmu.2020.01710
[20]	Okamura T, Sumitomo S, Morita K, et al. TGF-β3-expressing CD4⁺CD25(-)LAG3⁺ regulatory T cells control humoral immune responses[J]. Nat Commun, 2015,6:6329. DOI: 10.1038/ncomms7329. doi: 10.1038/ncomms7329
[21]	Toor SM, Syed Khaja AS, Alkurd I, et al. In-vitro effect of pembrolizumab on different T regulatory cell subsets[J]. Clin Exp Immunol, 2018,191(2):189-197. DOI: 10.1111/cei.13060. doi: 10.1111/cei.2018.191.issue-2
[22]	Yoshida K, Okamoto M, Sasaki J, et al. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells[J]. BMC Cancer, 2020,20(1):25. DOI: 10.1186/s12885-019-6499-y. doi: 10.1186/s12885-019-6499-y
[23]	Kamada T, Togashi Y, Tay C, et al. PD-1⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J]. Proc Natl Acad Sci U S A, 2019,116(20):9999-10008. DOI: 10.1073/pnas.1822001116. doi: 10.1073/pnas.1822001116
[24]	Wen L, Lu H, Li Q, et al. Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis[J]. J Exp Clin Cancer Res, 2019,38(1):299. DOI: 10.1186/s13046-019-1185-0. doi: 10.1186/s13046-019-1185-0
[25]	Oweida A, Hararah MK, Phan A, et al. Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regula-tory T-cell infiltration[J]. Clin Cancer Res, 2018,24(21):5368-5380. DOI: 10.1158/1078-0432.CCR-18-1038. doi: 10.1158/1078-0432.CCR-18-1038 pmid: 30042205
[26]	Di Pilato M, Kim EY, Cadilha BL, et al. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint the-rapy[J]. Nature, 2019,570(7759):112-116. DOI: 10.1038/s41586-019-1215-2. doi: 10.1038/s41586-019-1215-2 pmid: 31092922
[27]	Jacquelot N, Yamazaki T, Roberti MP, et al. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade[J]. Cell Res, 2019,29(10):846-861. DOI: 10.1038/s41422-019-0224-x. doi: 10.1038/s41422-019-0224-x